PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31721468-0	2020	The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.	crizotinib	129-139	ALK receptor tyrosine kinase	Homo sapiens	62-65	
31721468-5	2020	METHODS: This is a retrospective single-center study and enrolled 113 staged IIIB-IV ALK-positive NSCLC patients who had received crizotinib treatment.	crizotinib	130-140	ALK receptor tyrosine kinase	Homo sapiens	85-88	
31721468-12	2020	CONCLUSIONS: Trend of NLR, dNLR, PLR and WBC could be used to identify patients progress status in ALK-positive NSCLC patients receiving crizotinib.	crizotinib	137-147	ALK receptor tyrosine kinase	Homo sapiens	99-102